Street Calls of the Week
CAMBRIDGE, Mass. - Vyome Holdings, Inc. (NASDAQ:HIND), currently trading at $13.85 and showing a positive 4.57% year-to-date return according to InvestingPro, announced interim results from its Phase 2 proof-of-concept study showing that VT-1953 topical gel significantly reduced malodor in patients with malignant fungating wounds (MFW), according to a company press release.
The treatment demonstrated statistically significant improvement in the primary endpoint of reducing wound-associated malodor (P
MFW is a condition affecting 5-14% of advanced cancer patients when cancer cells break through the skin, creating chronic wounds with symptoms including extreme odor, severe pain, and psychological distress. According to recent research published in June 2025, an estimated 650,000 patients in the U.S. and approximately 10 million globally suffer from this condition.
"Despite a large number of cancer patients suffering from the symptoms of MFW, there are no FDA-approved options," said Dr. Shiladitya Sengupta, Vyome co-founder and Associate Professor of Medicine at Harvard Medical School.
The company plans to share additional details about the interim results and the MFW market during a live video conference on Monday, September 8. Full study results are expected in October 2026.
VT-1953 works by targeting TLR-MD2 and DNA gyrase to exert an immuno-anti-inflammatory effect. The gel has been well-tolerated in over 500 patients across prior clinical studies, with no clinically significant adverse trends noted in the current trial.
Vyome CEO Venkat Nelabhotla stated the company anticipates interacting with the FDA in early 2026 regarding this program, which addresses what the company estimates as a $1 billion market opportunity in the United States. With a current market capitalization of $13 million and trading near its 52-week high of $14.89, investors seeking deeper insights can access comprehensive analysis through InvestingPro’s detailed research reports.
The interim results were first presented at the recent annual meeting of the American Association for Cancer Research. For investors interested in following Vyome’s development pipeline and market potential, InvestingPro offers exclusive financial metrics, real-time alerts, and expert analysis as part of its comprehensive coverage of over 1,400 US stocks.
In other recent news, Vyome Holdings, Inc. completed its merger with Vyome Therapeutics, resulting in Vyome Therapeutics becoming a wholly owned subsidiary. The company has filed financial statements and management discussions related to the merger with the Securities and Exchange Commission. Additionally, Vyome Holdings has amended its Equity Distribution Agreement to increase its at-the-market public offering, allowing the issuance of up to $12 million in shares. In a strategic move, Vyome has partnered with Embryyo Technologies to explore opportunities in the AI-enabled medical device market. The company has also appointed Kreit & Chiu CPA LLP as its new independent registered public accounting firm, replacing Haskell & White LLP. Vyome Holdings’ Board of Directors is reviewing strategic options for its majority-owned subsidiary, Livechain Inc., to explore new opportunities. Lastly, following its merger with ReShape Lifesciences, Vyome Holdings will begin trading on Nasdaq under the ticker symbol "HIND."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.